Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Larry G. who wrote (453)	3/13/1999 11:45:00 AM
From: Sean Janzen	Read Replies (2) \| Respond to of 792

The low volume / low share price is a supply and demand issue. I don't find this event worrisome. It is my understanding that 80% of drugs that enter Phase I successfully reach Phase II. I don't expect to see a huge appreciation in the share price associated with completion of Phase I. MBI must continue to do what they are doing. They must continue to develop their drug portfolio and bring more drugs into human clinical testing. Any big gains in MBI are probably 2-3 years away. It is my intention to accumulate MBI on dips below $2.00.